Free shipping on orders 199.99$ and over

MS-TRA-5 Medsup COVID-19 Rapid Antigen Test

MS-TRA-5 Medsup COVID-19 Rapid Antigen Test

Regular price
Sale price
Regular price
Sold out
Unit price

Medsup Medical certifies that our Covid-19 rapid tests efficiency is not affected by the new variant of concern ERIS EG.5

The Medsup COVID-19 Rapid Antigen Test is a lateral flow chromatographic immunoassay for the qualitative detection the nucleocapsid protein antigen from SARS-CoV-2 in nasal swab specimens directly from individuals who are suspected of COVID-19 by their healthcare provider within the first seven days of the onset of symptoms.

  • Sensitivity 97.1% (95% CI= 93.1% ~ 98.9%)
  • Specificity 99.5% (95% CI= 98.2% ~ 99.9%)
  • Total Coincidence Rate 98.8% (95% CI= 97.6% ~ 99.5%)
  • Contents: 5 Test Cassettes, 5 Extraction Buffer Tubes, 5 Disposable Nasal Swabs, 1 Packaging Insert
  • Time for result: 15 to 30 minutes
  • Conservation: Keep at 2℃ - 30℃, keep dry
  • Expiry date: 24 months after manufacturing (current batch expires 2024-02)
  • Authorized by Health Canada
  • Assembled in Canada by MedSup Medical
  • Recyclable with Go Zero.

The Medsup COVID-19 Rapid Antigen Test can also test specimens from individuals without symptoms or other reasons to suspect COVID-19 infection when tested twice over two (or three days) with at least 24 hours (and no more than 36 hours) between tests. The SARS-CoV-2 Antigen Rapid Test does not differentiate between SARS-CoV and SARS-CoV-2.

Results are for the identification of SARS-CoV-2 nucleocapsid antigen. This antigen is generally detectable in upper respiratory samples during the acute phase of infection.

Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease.

Negative results, from patients with symptom beyond seven days, should be treated as presumptive and confirmed with a molecular assay, if necessary, for patient management. Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19.

The Medsup COVID-19 Rapid Antigen Test is intended for use by trained clinical laboratory personnel and individuals trained in point of care settings.